{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:03:44Z","timestamp":1789556624722,"version":"build-2803163510"},"reference-count":111,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and is increasingly recognized as a major contributor to liver-related and cardiometabolic morbidity. In people living with HIV (PLWH), the burden of MASLD is disproportionately high and continues to rise in the era of effective antiretroviral therapy (ART). The recent redefinition of MASLD underscores a paradigm shift toward metabolic dysfunction as a central driver of disease pathogenesis, a concept that is particularly relevant in the context of HIV infection. In PLWH, MASLD may represent a distinct immunometabolic condition in which conventional metabolic risk factors interact with chronic immune activation, persistent inflammation, ART exposure, and gut\u2013liver axis dysfunction. These factors may contribute to steatosis and fibrosis and complicate conventional obesity-based screening and risk stratification. This narrative review summarizes the disease burden, immunometabolic mechanisms, diagnosis, and management of MASLD in PLWH and identifies priorities for research and clinical care. Management requires integrated assessment of metabolic dysfunction, persistent inflammation, cumulative ART exposure, and cardiovascular risk rather than reliance on obesity-based screening alone.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1875819","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:21:00Z","timestamp":1789554060000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic dysfunction-associated steatotic liver disease in people living with HIV: mechanisms, diagnosis, and management"],"prefix":"10.3389","volume":"17","author":[{"given":"Ruoli","family":"Yu","sequence":"first","affiliation":[{"name":"Shanghai Public Health Clinical Center, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"Shanghai Public Health Clinical Center, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[{"name":"Shanghai Public Health Clinical Center, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.10.018","article-title":"Expert panel review on nonalcoholic fatty liver disease in persons with human immunodeficiency virus","volume":"20","author":"Lake","year":"2022","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2021.04.008","article-title":"Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease","volume":"32","author":"Lim","year":"2021","journal-title":"Trends Endocrinol Metab TEM"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-021-03069-1","article-title":"Infections at the nexus of metabolic-associated fatty liver disease","volume":"95","author":"Boeckmans","year":"2021","journal-title":"Arch Toxicol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26072","article-title":"Uncovering the NAFLD burden in people living with HIV from high- and middle-income nations: a meta-analysis with a data gap from subsaharan africa","volume":"26","author":"Manzano-Nunez","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/hiv.13730","article-title":"Burden of liver steatosis and liver fibrosis in a large cohort of people living with HIV","volume":"25","author":"Laguno","year":"2024","journal-title":"HIV Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003671","article-title":"Hepatic steatosis and nonalcoholic fatty liver disease are common and associated with cardiometabolic risk in a primary prevention cohort of people with HIV","volume":"37","author":"Lake","year":"2023","journal-title":"AIDS Lond Engl"},{"key":"B8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12974-016-0510-1","article-title":"HIV-tat alters Connexin43 expression and trafficking in human astrocytes: role in NeuroAIDS","volume":"13","author":"Berman","year":"2016","journal-title":"J Neuroinflamm"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2016.1227722","article-title":"CD4-gp120 interaction interface - a gateway for HIV-1 infection in human: molecular network, modeling and docking studies","volume":"35","author":"Pandey","year":"2017","journal-title":"J Biomol Struct Dyn"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.657679","article-title":"Gut microbiome homeostasis and the CD4 T- follicular helper cell IgA axis in human immunodeficiency virus infection","volume":"12","author":"Onabajo","year":"2021","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2025.101330","article-title":"The association of steatotic liver disease with cardiometabolic criteria and cardiovascular disease risk in a large cohort of people living with human immunodeficiency virus","volume":"24","author":"Sterling","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.66.1.81","article-title":"Non-alcoholic fatty liver disease in patients infected with human immunodeficiency virus: a systematic review","volume":"66","author":"Pires","year":"2020","journal-title":"Rev Assoc Med Bras 1992"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102679","article-title":"Indian patients with human immunodeficiency virus infection have high prevalence but mild severity of non-alcoholic fatty liver disease","volume":"16","author":"De","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa430","article-title":"Prevalence, predictors, and severity of lean nonalcoholic fatty liver disease in patients living with human immunodeficiency virus","volume":"71","author":"Cervo","year":"2020","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.85415","article-title":"Metabolic dysfunction-associated steatotic liver disease in people living with HIV\/AIDS: unraveling the paradox of lean phenotype and fibrosis","volume":"17","author":"George","year":"2025","journal-title":"Cureus"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf369","article-title":"Prevalence and risk factors of liver fibrosis among people with HIV and metabolic dysfunction-associated steatotic liver disease","volume":"12","author":"Xu","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1316471","article-title":"Nonalcoholic fatty liver disease and HIV infection","volume":"32","author":"Vallet-Pichard","year":"2012","journal-title":"Semin Liver Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002133","article-title":"Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocation","volume":"33","author":"Maurice","year":"2019","journal-title":"AIDS"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab019","article-title":"Growth hormone releasing hormone reduces circulating markers of immune activation in parallel with effects on hepatic immune pathways in individuals with HIV-infection and nonalcoholic fatty liver disease","volume":"73","author":"Stanley","year":"2021","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"B20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2012-07-409755","article-title":"The split personality of regulatory T cells in HIV infection","volume":"121","author":"Chevalier","year":"2013","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e32834577b3","article-title":"Th17 cells and regulatory T cells in elite control over HIV and SIV","volume":"6","author":"Hartigan-O\u2019Connor","year":"2011","journal-title":"Curr Opin HIV AIDS"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.967410","article-title":"CD4+ T cell activation and inflammation in NASH-related fibrosis","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/life13040949","article-title":"Molecular mechanism of sirtuin 1 inhibition by human immunodeficiency virus 1 tat protein","volume":"13","author":"Adolph","year":"2023","journal-title":"Life"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/cells15020117","article-title":"miR-204 negatively regulates HIV-tat-mediated inflammation in cervical epithelial cells via the NF-\u03baB axis: insights from an In vitro study","volume":"15","author":"Akolkar","year":"2026","journal-title":"Cells"},{"key":"B25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.nbd.2017.04.015","article-title":"HIV, tat and dopamine transmission","volume":"105","author":"Gaskill","year":"2017","journal-title":"Neurobiol Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1621338","article-title":"HIV-tat and vascular endothelium: implications in the HIV associated brain, heart, and lung complications","volume":"16","author":"Chandran","year":"2025","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1568762","article-title":"HIV-tat upregulates the expression of senescence biomarkers in CD4+ T-cells","volume":"16","author":"Casanova","year":"2025","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1189\/jlb.0306135","article-title":"Role of gp120 in dendritic cell dysfunction in HIV infection","volume":"80","author":"Chougnet","year":"2006","journal-title":"J Leukoc Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.163287","article-title":"gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis","volume":"59","author":"Bruno","year":"2010","journal-title":"Gut"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000952","article-title":"Metabolic dysfunction-associated steatotic liver disease in people with HIV","volume":"20","author":"Gattu","year":"2025","journal-title":"Curr Opin HIV AIDS"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13102513","article-title":"From steatosis to immunosenescence: the impact of metabolic dysfunction on immune aging in HIV and non-HIV populations","volume":"13","author":"Acierno","year":"2025","journal-title":"Biomedicines"},{"key":"B32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12929-024-01064-z","article-title":"Low-level HIV-1 viremia affects T-cell activation and senescence in long-term treated adults in the INSTI era","volume":"31","author":"Lara-Aguilar","year":"2024","journal-title":"J BioMed Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.125.326836","article-title":"Monocyte Dll4 contributes to systemic inflammation in people living with HIV","volume":"139","author":"Wang","year":"2026","journal-title":"Circ Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac475","article-title":"Proteomic analysis of hepatic fibrosis in human immunodeficiency virus-associated nonalcoholic fatty liver disease demonstrates up-regulation of immune response and tissue repair pathways","volume":"227","author":"Fourman","year":"2023","journal-title":"J Infect Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12823","article-title":"T-cell exhaustion in HIV infection","volume":"292","author":"Fenwick","year":"2019","journal-title":"Immunol Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03233-8","article-title":"Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH","volume":"592","author":"Dudek","year":"2021","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155573","article-title":"Changes in liver steatosis in HIV-positive women are associated with the BMI, but not with biomarkers","volume":"144","author":"Fernandez-Botran","year":"2021","journal-title":"Cytokine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000004189","article-title":"Microbial translocation and gut damage is associated with hepatic fibrosis but not steatosis in women with and without HIV","volume":"39","author":"Duarte","year":"2025","journal-title":"AIDS"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/1755-1536-3-21","article-title":"Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis","volume":"3","author":"Guo","year":"2010","journal-title":"Fibrogenesis Tissue Repair"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGF-beta signaling and hepatic fibrosis","volume":"13","author":"Seki","year":"2007","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1013175","article-title":"Liver biopsies obtained throughout SIV infection reveal evolving interferon stimulated protein expression within distinct monocyte\/macrophage subsets","volume":"21","author":"Derby","year":"2025","journal-title":"PloS Pathog"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003435","article-title":"Pro-fibrogenic role of alarmin high mobility group box 1 in HIV-hepatitis B virus coinfection","volume":"37","author":"Singh","year":"2023","journal-title":"AIDS"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J Hepatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.07.041","article-title":"Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis","volume":"74","author":"Gaul","year":"2021","journal-title":"J Hepatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2023.03.002","article-title":"The multifaceted roles of macrophages in NAFLD pathogenesis","volume":"15","author":"Vonderlin","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.immuni.2020.04.001","article-title":"Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis","volume":"52","author":"Seidman","year":"2020","journal-title":"Immunity"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1631-3","article-title":"Resolving the fibrotic niche of human liver cirrhosis at single-cell level","volume":"575","author":"Ramachandran","year":"2019","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1297378","article-title":"A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease","volume":"14","author":"Mart\u00ednez-Sanz","year":"2023","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178165","article-title":"Distinct gut microbiota signatures are associated with severity of metabolic dysfunction-associated steatotic liver disease in people with HIV","volume":"26","author":"Righetti","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155952","article-title":"The lipopolysaccharide-TLR4 axis regulates hepatic glutaminase 1 expression promoting liver ammonia build-up as steatotic liver disease progresses to steatohepatitis","volume":"158","author":"Mercado-G\u00f3mez","year":"2024","journal-title":"Metabolism"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118633","article-title":"The pathogenesis of metabolic dysfunction-associated steatotic liver disease and nucleoside reverse transcriptase inhibitors (NRTIs) -based HIV-antiretroviral regimens: a comprehensive narrative review","volume":"192","author":"Horn","year":"2025","journal-title":"BioMed Pharmacother Biomedecine Pharmacother"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/life14060742","article-title":"Metabolic dysfunction-associated steatotic liver disease in people living with HIV-limitations on antiretroviral therapy selection","volume":"14","author":"Kalopitas","year":"2024","journal-title":"Life Basel Switz"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1309\/8B8B-J6AP-5KGV-7C1H","article-title":"Toxic effects of nucleoside reverse transcriptase inhibitors on the liver. Value of electron microscopy analysis for the diagnosis of mitochondrial cytopathy","volume":"119","author":"Duong Van Huyen","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01417.x","article-title":"Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV\/HCV-coinfected patients","volume":"18","author":"Loko","year":"2011","journal-title":"J Viral Hepat"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101116","article-title":"Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART)","volume":"40","author":"Bischoff","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000760","article-title":"Causes and outcomes of hepatic fibrosis in persons living with HIV","volume":"17","author":"Yen","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf049","article-title":"Noninvasive markers of hepatic steatosis and fibrosis following integrase strand-transfer inhibitor initiation in women with HIV","volume":"81","author":"Yu","year":"2025","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/metabo15110695","article-title":"Metabolomic profile of weight gain of people living with HIV treated with integrase strand transfer inhibitor regimens reveals dysregulated lipid metabolism and mitochondrial dysfunction","volume":"15","author":"Ascencio-Anastacio","year":"2025","journal-title":"Metabolites"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa259","article-title":"The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human\/simian adipose tissue and human adipocytes","volume":"71","author":"Gorwood","year":"2020","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/cells11111841","article-title":"Inhibition of adipose tissue beiging by HIV integrase inhibitors, dolutegravir and bictegravir, is associated with adipocyte hypertrophy, hypoxia, elevated fibrosis, and insulin resistance in simian adipose tissue and human adipocytes","volume":"11","author":"Ngono Ayissi","year":"2022","journal-title":"Cells"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021922","article-title":"Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy","volume":"88","author":"Sutinen","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2015.01.002","article-title":"Adipocytokines and hepatic fibrosis","volume":"26","author":"Saxena","year":"2015","journal-title":"Trends Endocrinol Metab TEM"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283400088","article-title":"Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients","volume":"24","author":"Domingo","year":"2010","journal-title":"AIDS"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1303","article-title":"Fatty liver disease in a prospective north american cohort of adults with human immunodeficiency virus and hepatitis B virus coinfection","volume":"73","author":"Khalili","year":"2021","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz281","article-title":"High kynurenine:tryptophan ratio is associated with liver fibrosis in HIV-monoinfected and HIV\/hepatitis C virus-coinfected women","volume":"6","author":"Kardashian","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"B67","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/hiv.12638","article-title":"In vivo evidence that the cannabinoid receptor 2-63 RR variant is associated with the acquisition and\/or expansion of HIV infection","volume":"19","author":"Sagnelli","year":"2018","journal-title":"HIV Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181890","article-title":"Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV\/HCV coinfected patients","volume":"12","author":"Sagnelli","year":"2017","journal-title":"PloS One"},{"key":"B69","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/ajg.2014.32","article-title":"Risk factors for fatty liver in the multicenter AIDS cohort study","volume":"109","author":"Price","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/v14061313","article-title":"Immunometabolic reprogramming in response to HIV infection is not fully normalized by suppressive antiretroviral therapy","volume":"14","author":"Deme","year":"2022","journal-title":"Viruses"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-020-00484-4","article-title":"Dysfunctional immunometabolism in HIV infection: contributing factors and implications for age-related comorbid diseases","volume":"17","author":"Butterfield","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000313","article-title":"Burden of fatty liver and hepatic fibrosis in persons with HIV: a diverse cross-sectional US multicenter study","volume":"78","author":"Gawrieh","year":"2023","journal-title":"Hepatology"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13274","article-title":"Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV","volume":"23","author":"Cervo","year":"2022","journal-title":"HIV Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001773","article-title":"FIB-4 fails to identify significant liver fibrosis in people with HIV: a large multinational screening study","author":"Cinque","year":"2026","journal-title":"Hepatology"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12020282","article-title":"Two-tier care pathways for liver fibrosis associated to non-alcoholic fatty liver disease in HIV mono-infected patients","volume":"12","author":"Sebastiani","year":"2022","journal-title":"J Pers Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"558\u201366","DOI":"10.1097\/QAD.0000000000004419","article-title":"Risk factors of metabolic dysfunction-associated fatty liver disease in people living with HIV receiving antiretroviral therapy","volume":"40","author":"Yuan","year":"2025","journal-title":"AIDS Lond Engl"},{"key":"B78","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/09564624241287886","article-title":"Incidence of non-alcoholic fatty liver disease in antiretroviral therapy-na\u00efve people with human immunodeficiency virus who start DTG\/ABC\/3TC compared to BIC\/FTC\/TAF at 48-week follow-up","volume":"36","author":"Cano D\u00edaz","year":"2025","journal-title":"Int J STD AIDS"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae411","article-title":"External validation of serologic scores for the detection of liver steatosis among people with HIV","volume":"11","author":"Riebensahm","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa429","article-title":"Optimal threshold of controlled attenuation parameter for detection of HIV-associated NAFLD with magnetic resonance imaging as the reference standard","volume":"72","author":"Ajmera","year":"2021","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002700","article-title":"Diagnostic ability of simple noninvasive blood tests to predict increased liver stiffness in people living with HIV and steatotic liver disease","volume":"119","author":"Sterling","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cgh.2022.03.048","article-title":"Screening HIV patients at risk for NAFLD using MRI-PDFF and transient elastography: a european multicenter prospective study","volume":"21","author":"Lemoine","year":"2023","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30674","article-title":"MRI assessment of treatment response in HIV-associated NAFLD: a randomized trial of a stearoyl-coenzyme-a-desaturase-1 inhibitor (ARRIVE trial)","volume":"70","author":"Ajmera","year":"2019","journal-title":"Hepatology"},{"key":"B84","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.cgh.2022.01.023","article-title":"Two-step strategy, FIB-4 followed by magnetic resonance elastography, for detecting advanced fibrosis in NAFLD","volume":"21","author":"Tamaki","year":"2023","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"B85","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/HEP.0000000000000843","article-title":"AASLD practice guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis","volume":"81","author":"Sterling","year":"2025","journal-title":"Hepatology"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/nu15081990","article-title":"Nutritional and lifestyle therapy for NAFLD in people with HIV","volume":"15","author":"Cinque","year":"2023","journal-title":"Nutrients"},{"key":"B87","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000616","article-title":"Weight gain and integrase inhibitors","volume":"33","author":"Eckard","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.7326\/M20-4853","article-title":"Weight and metabolic changes after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: a cohort study","volume":"174","author":"Surial","year":"2021","journal-title":"Ann Intern Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12071454","article-title":"Rilpivirine activates STAT1 in non-parenchymal cells to regulate liver injury in people living with HIV and MASLD","volume":"12","author":"Moragrega","year":"2024","journal-title":"Biomedicines"},{"key":"B92","article-title":"Weighing In: glucagon-like peptide-1 receptor agonism for persons with HIV","volume":"32","author":"Thomas","year":"2024","journal-title":"Top Antivir Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.635556","article-title":"Effect of SGLT2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"12","author":"Wei","year":"2021","journal-title":"Front Endocrinol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.idnow.2025.105040","article-title":"Clinical, biological, metabolic, and immune changes associated with the use of sodium-glucose cotransporter 2 inhibitors in people living with HIV","volume":"55","author":"Guiraud","year":"2025","journal-title":"Infect Dis NOW"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab274","article-title":"Clinical adverse events associated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals","volume":"106","author":"Lin","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003965","article-title":"Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors","volume":"38","author":"Russo","year":"2024","journal-title":"AIDS"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30338-8","article-title":"Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial","volume":"6","author":"Stanley","year":"2019","journal-title":"Lancet HIV"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001608","article-title":"Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: november 2025 updates to AASLD practice guidance","volume":"83","author":"Bansal","year":"2026","journal-title":"Hepatology"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.7326\/M23-3354","article-title":"The effect of open-label semaglutide on metabolic dysfunction-associated steatotic liver disease in people with HIV","volume":"177","author":"Lake","year":"2024","journal-title":"Ann Intern Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2025.2478917","article-title":"Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis","volume":"26","author":"Bhushan","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"B102","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-076547","article-title":"Role of fatty liver in the epidemic of advanced chronic liver disease among people with HIV: protocol for the canadian LIVEHIV multicentre prospective cohort","volume":"13","author":"Cinque","year":"2023","journal-title":"BMJ Open"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf637","article-title":"Female sex is protective against MASLD with clinically significant fibrosis in a large cross-sectional cohort of persons with HIV","volume":"12","author":"Wegermann","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2025.102981","article-title":"Long-term effects of HCV eradication on lipid profiles associated with MASLD among people with HIV with advanced fibrosis or cirrhosis","volume":"18","author":"Virseda-Berdices","year":"2025","journal-title":"J Infect Public Health"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0270911","article-title":"The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV\/HIV infected subjects","volume":"17","author":"Cairoli","year":"2022","journal-title":"PloS One"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003947","article-title":"MAVMET trial: maraviroc and\/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIV","volume":"38","author":"McCabe","year":"2024","journal-title":"AIDS Lond Engl"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1638071","article-title":"Triglyceride-glucose index and FIB-4 score in relation to cardiovascular disease risk among people with HIV: a retrospective cohort study","volume":"12","author":"Montes","year":"2025","journal-title":"Front Med"},{"key":"B109","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11883-025-01298-8","article-title":"Statin use in special populations for the prevention of cardiovascular disease in adults","volume":"27","author":"Safarova","year":"2025","journal-title":"Curr Atheroscler Rep"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13080230","article-title":"Safety and efficacy of immune checkpoint inhibitors in human immunodeficiency virus-associated cancer: a systematic scoping review","volume":"13","author":"Alatawi","year":"2025","journal-title":"Diseases"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/ph18111654","article-title":"Evaluating the safety and efficacy of PD-1 inhibitors in HIV patients diagnosed with lung cancer: a systematic review","volume":"18","author":"Hetta","year":"2025","journal-title":"Pharmaceuticals"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1875819\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:21:02Z","timestamp":1789554062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1875819\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":111,"alternative-id":["10.3389\/fimmu.2026.1875819"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1875819","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1875819"}}